•   

     

     

  •   

     

     

  •       

          

PRONIA

PRONIA for Investors

The goal of the project PRONIA is to implement reliable and accessible prognostic tools that will facilitate the prediction and prevention of psychoses worldwide.

The long-term aim is also to provide commercial prognostic services through internet-based telemedicine applications. Therefore, cooperation and support of potential investors is of great value for the project.


This information is aimed at potential investors of PRONIA:

Our Vision

 

Psychoses typically commence in the most productive and critical period of life – late adolescence and early adulthood. In around 75-90 percent of the persons who develop the full-blown illness, there are early symptoms, such as mood swings, concentration lacking, exhaustion and reduced performance. To date, it is hard to say for an individual help-seeking person, whether such a psychological crises will develop into a psychotic disorder. This is where PRONIA sets in.


The aim of the researchers from five European countries and Australia is to develop an innovative prognostic tool on the basis of clinical, neurocognitive and neurobiological data analysed by means of pattern recognition algorithms. The PRONIA prognostic services will enable people all over the world to access and benefit from the individualized early risk profiling of psychotic disorders.

Our Project

 

Affective and non-affective psychoses frequently entail long-term disability and increased mortality in the affected patients. These factors drive the 6.3% of the global burden of disease caused by these disorders and account for the €207 billion per year in Europe alone spent due to direct and indirect costs. These figures emphasise that psychoses are the most expensive brain-related disorders, with a similar health-economic impact as cardiovascular diseases. A significant component in the reduction of this burden is to provide preventive treatments to those at highest risk of developing these devastating illnesses in the future. Therefore, reliable and accessible tools for an individualised early recognition of psychoses are increasingly in the focus of international mental healthcare policy and research.


Before these targeted interventions can become regularly and widely available, the prognostic certainty of diagnosis and the long-term functional outcome has to be improved. To this end, PRONIA is analysing the relationship between different kinds of quantitive data, so-called biomarkers, and the development of disease-related outcomes in 1700 study participants in total. The PRONIA consortium uses routine brain imaging, clinical psychological data, neurocognitive data, genomic and metabolomics analyses to discover new and evaluate existing biomarkers. Novel machine learning methods are being developed in parallel for the integration of the different kinds of data into viable criteria for robust prognostics. These novel tools have to become part of the normal diagnostic workflows in clinical psychiatry, so that the general public can access and benefit from PRONIA’s results.

 

The PRONIA consortium is developing an eHealth prototype providing telepsychiatric services for an accurate prediction of mental health-related disability in young help-seeking persons. This eHealth prototype will become available within the next five years and will pave the way for accurate, personalized diagnostics for persons at risk that can be employed all over the world.

Your investment in PRONIA

 

PRONIA’s ultimate goal is to realise licensing, commercialisation and sustained engineering strategies of its early recognition services through broadly available telemedicine applications. The undefinedPRONIA patent application „Adaptive pattern recognition for psychosis risk modelling“ was filed in August 2014 and is presently pending.


This will provide tools for psychosis risk profiling to diverse target groups in healthcare markets, including primary care-givers, medical practitioners, hospitals, health insurances, the pharmaceutical industry and research institutions.
PRONIA’s products will provide firm diagnostic grounds for preventive therapy, improving outcomes and reducing costs. Thus, they will offer a unique selling proposition to the mental health sectors in Europe and beyond.

Project facts

 

  • 1700 people are being recruited for the clinical studies
  • PRONIA is aiming to raise the prognostic certainty for future disease development to up to 90 percent
  • 6 Million Euros in project funding provided by the European Commission (FP7)
  • 5 years of funding for the project started on 1/10/2013
  • PRONIA has 11 partners from 5 European countries and Australia
  • PRONIA is coordinated by Prof. Dr. Nikolaos Koutsouleris from the Ludwig-Maximilian-University Munich, Germany

 

PRONIA IP Experts

 

undefinedStellbrink IP and undefinedArnason Stellbrink are pleased to be a part of that revolution and are very happy about the rising success of their client.

Home
Menu
Search
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

News Section

PRONIA Coordinator receives award for personalised medicine Read more

Press Area

+++ Information about PRONIA for the Press and Press Events +++

+++ Latest PRONIA Publications +++